Compare Stocks → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:OCX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOCXOncoCyte$2.46$2.92$2.08▼$6.20$20.34M0.848,167 shs40,509 shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOCXOncoCyte-2.58%-10.73%-19.77%-25.38%-53.68%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationOCXOncoCyte1.2463 of 5 stars3.31.00.00.01.12.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOCXOncoCyte2.50Moderate Buy$4.0665.14% UpsideCurrent Analyst RatingsLatest OCX and DDDD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2024OCXOncoCyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$3.60 ➝ $4.254/17/2024OCXOncoCyteStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingEqual Weight ➝ Equal Weight$4.004/15/2024OCXOncoCyteBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSpeculative Buy ➝ Speculative Buy$5.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOCXOncoCyte$1.50M13.56N/AN/A$2.48 per share0.99Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOCXOncoCyte-$27.78MN/A0.00∞N/A-1,890.62%-96.30%-41.12%5/9/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthOCXOncoCyteN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOCXOncoCyteN/A1.491.49OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOCXOncoCyte55.35%Insider OwnershipCompanyInsider OwnershipOCXOncoCyte1.94%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableOCXOncoCyte758.27 million8.11 millionNo DataOCX and DDDD HeadlinesSourceHeadlineStrong Future Outlook for OncoCyte: Buy Rating and Increased Price Target Amid Positive Partnerships and Financial Efficiencymarkets.businessinsider.com - April 24 at 6:06 PMOncoCyte (NASDAQ:OCX) Earns Sell Rating from Analysts at StockNews.comamericanbankingnews.com - April 24 at 2:22 AMBuffett Grabs More of This Stock, Plus Other Notable Insider Buyingmsn.com - April 22 at 12:51 AMStephens Reiterates "Equal Weight" Rating for OncoCyte (NASDAQ:OCX)americanbankingnews.com - April 19 at 5:50 AMOncoCyte (NASDAQ:OCX) Now Covered by StockNews.comamericanbankingnews.com - April 18 at 2:30 AMOncoCyte Co. (NASDAQ:OCX) CEO Josh Riggs Buys 3,390 Sharesamericanbankingnews.com - April 16 at 6:58 AMOncoCyte Co. (NASDAQ:OCX) Director Andrew Arno Acquires 33,898 Shares of Stockamericanbankingnews.com - April 16 at 5:44 AMOncoCyte (NASDAQ:OCX) Given Speculative Buy Rating at Benchmarkamericanbankingnews.com - April 16 at 4:50 AMOncoCyte Co. (NASDAQ:OCX) CEO Buys $10,000.50 in Stockinsidertrades.com - April 16 at 4:46 AMOncoCyte Co. (NASDAQ:OCX) Major Shareholder Broadwood Partners, L.P. Buys 2,420,000 Shares of Stockamericanbankingnews.com - April 16 at 4:18 AMOncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcriptseekingalpha.com - April 13 at 10:47 PMQ4 2023 OncoCyte Corp Earnings Callfinance.yahoo.com - April 13 at 1:38 AMOCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023investorplace.com - April 12 at 12:00 PMTop 3 Health Care Stocks That May Collapse In Q2msn.com - April 12 at 10:36 AMOncoCyte Corporation: Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assayfinanznachrichten.de - April 12 at 10:10 AMS&P Futures Tick Lower as Investors Digest Big Bank Earningsmsn.com - April 12 at 10:10 AMS&P Futures Tick Lower as Investors Cautiously Await U.S. Big Bank Earningsmsn.com - April 12 at 7:32 AMOncocyte announces $15.8 mln private placement of securitiesmsn.com - April 12 at 7:32 AMONCOCYTE REPORTS Full Year 2023 FINANCIAL RESULTSprismmediawire.com - April 12 at 6:00 AMOncocyte Reports Full Year 2023 Financial Resultsglobenewswire.com - April 12 at 6:00 AMOncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rulesprismmediawire.com - April 11 at 9:48 PMOncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rulesglobenewswire.com - April 11 at 9:46 PMOncocyte and Bio-Rad Partner on Global Launch of Transplant Assayglobenewswire.com - April 11 at 5:30 PMHere's what Wall Street expects from Oncocyte's earningsmarkets.businessinsider.com - April 11 at 12:51 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsOncoCyteNASDAQ:OCXOncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.